Chinese scientists have mapped the world's most "toxic" breast cancer

Chinese Three Negative Breast Cancer Genome Map
8 March, International Women's Day.
of the same day, cancer cells, a leading international oncology journal, published an important study by Chinese scientists.
Led by Professor Zhai Zhimin, Director of Surgery and Breast Surgery at Fudan University-affiliated Oncology Hospital and Director of the Institute of Oncology, Fudan University, including Executive Director of the Precision Oncology Center of Fudan University-affiliated Oncology Hospital, Huang Wei Researcher Team of the National Human Genome Research Center of Shanghai Academy of Sciences, Fudan University School of Life Sciences and After more than 4 years of joint research, four teams, such as Professor Shi Leming of Fudan University's affiliated Oncology Hospital and Professor Wang Peng of the Shanghai Institute of Advanced Studies of the Chinese Academy of Sciences, successfully mapped the world's largest multi-group map of three-negative breast cancer cohorts and proposed "precision treatment strategies based on the molecular division of three-negative breast cancer"." breast cancer like a 'big family', can be subdivided into cavity A, cavity B, HER-2 positive and three negative four subtypes, of which three negative breast cancer is the most 'toxic' one. Zhai Zhimin told China Science Daily, "Three-negative breast cancer is called 'three yin', precisely because this breast cancer subtype of estrogen- and progesterone-like and HER-2 three main therapeutic targets are negative." Compared with the other three breast cancer subtypes, triple-negative breast cancer can only rely on chemotherapy, and the treatment effect is not good, which is a worldwide problem in the field of breast cancer. "
" anti-cancer drugs to play a role, we must first find a role in the tumor 'target', this 'target' is what we usually call drug targets, different types of cancer drug targets often have a large difference," Zhai Zhimin further explained, "the lack of specific therapeutic targets is the main reason for the long-term lack of good treatment for triple negative breast cancer."
At present, the treatment of triple-negative breast cancer is mainly chemotherapy, but even so, a considerable number of patients still bear the pain caused by the toxic side effects of chemotherapy, and because "blind" chemotherapy is prone to drug resistance and ineffective, three years after the recurrence rate will reach 40%-50%;three-negative breast cancer accounts for about 20% of the total breast cancer, and the proportion of young patients in China is even higher. And a growing body of research suggests that triple negative breast cancer may not be a single type.
" Previously, Zhai Zhimin team for different efficacy of three-negative breast cancer has carried out a study, that is, different prognosis of three-negative breast cancer to distinguish, and then provide different diagnosis and treatment strategies: poor prognosis of three-negative breast cancer, can use targeted treatment of combined chemotherapy strategy to improve the treatment effect, thus bringing new hope for treatment, but also for in-depth exploration of three-negative breast cancer to raise deep-seated scientific questions: what kind of "group" characteristics of this type of breast cancer? What is the relationship with clinical esogeology? That's what we're trying to explore in this study. Huang Wei said in an interview, "To this end, the researchers jointly conducted a study of 465 clinical samples of triple-negative breast cancer, to map Chinese of the three-negative breast cancer queue multi-group.
Through the analysis of huge genetic data, it is proved that triple negative breast cancer is not really a single type in the traditional understanding - three negative breast cancer not only has its own "family", but also family members have their own "group" characteristics, thus forming different subtypes, and there may be differences in survival between different subtypes and sensitivity to different treatment options.
are the most "toxic" breast cancer subsypes? Previously, all the three negative breast cancer research topics in the world have not given a clear answer. The team used a large amount of data to analyze the three-negative breast cancer subtype with some common characteristics gradually became clear. Based on the different characteristics of these subtype surface proteins, the researchers classified triple negative breast cancer and named it four different subtypes: immunomodulation type, cavity androgen-like body type, substrate-like immunosuppressive type, and interstitial type. This is also the first time in the world based on the multi-dimensional big data system proposed three-negative breast cancer classification standards, which for the search for three-negative breast cancer target points out a new direction.
the researchers further analyzed the different subtypes of triple-negative breast cancer and found the unique genetic locations of the different subtypes. "In fact, the team of experts named different subsypes based on different characteristics of cancer cells." Dr. Jiang 1zhou, the first author of the paper, said that compared with other subtypes, such breast cancer cells are surrounded by a large number of lymphocytes, may be sensitive to immunotherapy, while cavity androgen-like breast cancer cells have obvious HER-2 gene mutations, may be applicable to targeted targeted treatment.three-negative breast cancer is expected to be "targeted therapy" in the future. At present, zhai Zhimin team based on the results of the previous experiments invented a clinically practical three-negative breast cancer molecular division method, combined with breast surgery is vigorously promoting precision medical genetic testing, for each patient to carry out accurate molecular genotyping and identification of drug targets, so as to achieve precision treatment in the clinic.
It is understood that Fudan University Affiliated Oncology Hospital has conducted a clinical study on the precise treatment of resoicable tri-negative breast cancer, the FUTURE study, the project was approved by the Ethics Committee, trying to accurately divide the three-negative breast cancer according to the characteristics of the patient's respective genetic variation points, precisely divided into seven different target arms. The naming of this clinical trial also represents its connotation, the future direction of three-negative breast cancer is also classified and treated, hoping to improve the survival of three-negative breast cancer patients is no longer a distant dream. For patients with advanced triple-negative breast cancer who are resistant to chemotherapy, it can be said that it brings vitality and dawn.
Zhimin said that the unique genetic mutations of different subtypes are the "beacon" of clinical transformation research, breaking the previous three-negative breast cancer treatment "fuzzy direction" difficulties, helping medical experts to "targeted." Based on basic research data, the researchers also proposed "precision treatment strategies based on the molecular division of triple negative breast cancer." For these specific gene mutation studies, combined with clinical trials, there is an opportunity to achieve clinical transformation earlier and to develop drugs for different three-negative breast cancer targets faster, allowing patients to obtain accurate and significantly improved outcomes as early as possible.
same time, the study also published for the first time a number of Chinese thred-negative breast cancer-based gene mutations: such as the PIC3CA gene mutation, the proportion of patients with triple-negative breast cancer in China is significantly higher than in Europe and the United States data."
" This study draws a multi-group map of Chinese thredi-negative breast cancer will be conducive to the discovery of more specific targets suitable for patients with triple-negative breast cancer in China, for the follow-up of Chinese thred-negative breast cancer drug research and development, clinical trials to provide data and evidence support." Huang Wei said that in the future, these "histology" and clinical big data will be integrated for interdisciplinary collaborative and innovative research, with a view to expanding the means and scope of clinical transformation research, so as to make it possible to accurate diagnosis and treatment of malignant tumors such as triple negative breast cancer, which seriously endanger human health. (Source: Science Network Huang Xin Wang Guangzhao)